Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model
Medical Mycology · 2023
DOI: 10.1093/mmy/myad113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Mycology, 2023. Verfasst von Jacqueline Teixeira da Silva und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Nano & Biotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, St 235 university sector, Goiân…. Hauptthemen laut MEDLINE: Candidiasis, Vulvovaginal, Chitosan, Propolis, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: CAPES.
Abstract (Originalsprache)
Vulvovaginal candidiasis (VVC) is a fungal infection caused mainly by Candida albicans. The treatment of VVC with azoles has been impaired due to the increased cases of resistance presented by this pathogen. The aim of the present study was to investigate the antifungal activity of mucoadhesive chitosan nanoparticles encapsulating both green propolis and fluconazole for topical use in the treatment of VVC. The nanoparticles were prepared by the ionic gelation method, resulting in a size of 316.5 nm containing 22 mg/kg of green propolis and 2.4 mg/kg of fluconazole. The nanoparticles were non-toxic in vitro using red blood cells or in vivo in a Galleria mellonella toxicity model. The treatment of female BALB/c mice infected by C. albicans ATCC 10231 with topical nanoparticles co-encapsulating fluconazole and green propolis was effective even using a fluconazole amount 20 times lower than the amount of miconazole nitrate 2% cream. Considering that the mucoadhesive property of chitosan, which is known to allow a prolonged retention time of the compounds at the mucous epithelia, the antifungal potential of the phenols and flavonoids present in green propolis may have favored the effectiveness of this treatment. These results indicate that this formulation of topical use for fluconazole associated with green propolis can be used as a promising approach to therapy for the treatment of VVC, thus contributing to reducing the development of resistance to azoles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Nano & Biotechnology, Institute of Tropical Pathology and Public Health, Universidade Federal de Goiás, St 235 university sector, Goiânia, GO, 74605-050, Brazil.
- Laboratory of Pathology, Universidade Federal de Goiás, St 235 university sector, Goiânia, GO, 74605-050, Brazil.
- Pharmacy Course, School of Medical Sciences, Pharmaceuticals and Biomedical Sciences, Pontifícia Universidade Católica de Goiás, Av university, 1440, Goiânia, GO, 74175-120, Brazil.
- Company Citrinitas, St Pedroso Alvarenga, 505, São Paulo, SP, 04531-930, Brazil.
ORCID-Profile: Jacqueline Teixeira da Silva
Förderung
- CAPES
Zitieren
APA
da Silva, J. T., Dantas de Sousa, P. H., Costa, A. F., de Menezes, L. B., Alves, S. F., Pellegrini, F., & Amaral, A. C. (2023). Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model. Medical Mycology. https://doi.org/10.1093/mmy/myad113
Vancouver
da Silva JT, Dantas de Sousa PH, Costa AF, de Menezes LB, Alves SF, Pellegrini F, et al. Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model. Medical Mycology. 2023. doi:10.1093/mmy/myad113
BibTeX
@article{daSilva2023,
author = {da Silva, Jacqueline Teixeira and Dantas de Sousa, Paulo Henrique and Costa, Adelaide Fernandes and de Menezes, Liliana Borges and Alves, Suzana Ferreira and Pellegrini, Flavio and Amaral, Andre Correa},
title = {Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model},
journal = {Medical Mycology},
year = {2023},
doi = {10.1093/mmy/myad113}
}
EUVIMED